New drug data makes this French biotech stock a buy, says Jefferies
Analyst Faisal Khurshid upgraded the stock to buy from hold.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
